• Intelligent Bio Solutions posted fiscal Q3 revenue of $1.06 million, up 46% year over year, while net loss attributable to shareholders widened to $2.86 million.
• Gross margin expanded 3.67 percentage points to 50.5%, with cartridge sales rising 59% to $703,538 and representing 66% of quarterly revenue.
• Nine-month revenue rose 39% to $3.07 million, while net loss attributable to shareholders widened to $8.52 million.
• Cash and cash equivalents climbed to $6.86 million at March 31 from $740,371 at Dec. 31.
• Business update cited progress in FDA 510(k) work, including completion of a clinical cut-off study and initiation of a validation study for a rapid drug-screening cartridge targeting 70% faster results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130830PRIMZONEFULLFEED9719348) on May 13, 2026, and is solely responsible for the information contained therein.